These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19963397)

  • 1. Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry.
    Kaltashov IA; Bobst CE; Abzalimov RR; Berkowitz SA; Houde D
    J Am Soc Mass Spectrom; 2010 Mar; 21(3):323-37. PubMed ID: 19963397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based methods in characterization of the higher order structure of protein therapeutics.
    Kaltashov IA; Bobst CE; Pawlowski J; Wang G
    J Pharm Biomed Anal; 2020 May; 184():113169. PubMed ID: 32092629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced mass spectrometry-based methods for the analysis of conformational integrity of biopharmaceutical products.
    Bobst CE; Kaltashov IA
    Curr Pharm Biotechnol; 2011 Oct; 12(10):1517-29. PubMed ID: 21542797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches.
    Bobst CE; Abzalimov RR; Houde D; Kloczewiak M; Mhatre R; Berkowitz SA; Kaltashov IA
    Anal Chem; 2008 Oct; 80(19):7473-81. PubMed ID: 18729476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical quality control with mass spectrometry.
    Liu S; Schulz BL
    Bioanalysis; 2021 Aug; 13(16):1275-1291. PubMed ID: 34463131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics.
    Kaltashov IA; Bobst CE; Abzalimov RR; Wang G; Baykal B; Wang S
    Biotechnol Adv; 2012; 30(1):210-22. PubMed ID: 21619926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical Aspects of Biopharmaceuticals and their Study by Mass Spectrometry.
    David V; Borbala D; Laroly V; Laszlo D; Istvan A; Imre K; Krisztina L
    Acta Pharm Hung; 2016; 86(4):141-150. PubMed ID: 29870600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.
    Houde D; Berkowitz SA; Engen JR
    J Pharm Sci; 2011 Jun; 100(6):2071-86. PubMed ID: 21491437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MS-based conformation analysis of recombinant proteins in design, optimization and development of biopharmaceuticals.
    Goswami D; Zhang J; Bondarenko PV; Zhang Z
    Methods; 2018 Jul; 144():134-151. PubMed ID: 29678586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Utilization of Hydrogen/Deuterium Exchange in Biopharmaceutical Industry].
    Coufalová D; Vojtěšek B; Hernychova L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):59-63. PubMed ID: 27846722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solving Complex Biologics Truncation Problems by Top-Down Mass Spectrometry.
    Zhang Z; Hug C; Tao Y; Bitsch F; Yang Y
    J Am Soc Mass Spectrom; 2021 Aug; 32(8):1928-1935. PubMed ID: 33395284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulsed-alkylation mass spectrometry for the study of protein folding and dynamics: development and application to the study of a folding/unfolding intermediate of bacterial luciferase.
    Apuy JL; Park ZY; Swartz PD; Dangott LJ; Russell DH; Baldwin TO
    Biochemistry; 2001 Dec; 40(50):15153-63. PubMed ID: 11735398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of protein therapeutics by mass spectrometry: recent developments and future directions.
    Chen G; Warrack BM; Goodenough AK; Wei H; Wang-Iverson DB; Tymiak AA
    Drug Discov Today; 2011 Jan; 16(1-2):58-64. PubMed ID: 21093608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-resolution MS for structural characterization of protein therapeutics: advances and future directions.
    Wei H; Tymiak AA; Chen G
    Bioanalysis; 2013 May; 5(10):1299-313. PubMed ID: 23721450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in native high-performance liquid chromatography and intact mass spectrometry for the characterization of biopharmaceutical products.
    Tassi M; De Vos J; Chatterjee S; Sobott F; Bones J; Eeltink S
    J Sep Sci; 2018 Jan; 41(1):125-144. PubMed ID: 28990739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry.
    Huang RY; Chen G
    Anal Bioanal Chem; 2014 Oct; 406(26):6541-58. PubMed ID: 24948090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Getting to the core of protein pharmaceuticals--Comprehensive structure analysis by mass spectrometry.
    Leurs U; Mistarz UH; Rand KD
    Eur J Pharm Biopharm; 2015 Jun; 93():95-109. PubMed ID: 25791210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mass spectrometry in the characterization of biologic protein products.
    Rathore D; Faustino A; Schiel J; Pang E; Boyne M; Rogstad S
    Expert Rev Proteomics; 2018 May; 15(5):431-449. PubMed ID: 29694790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technical decision making with higher order structure data: utilization of differential scanning calorimetry to elucidate critical protein structural changes resulting from oxidation.
    Arthur KK; Dinh N; Gabrielson JP
    J Pharm Sci; 2015 Apr; 104(4):1548-54. PubMed ID: 25561411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and QC of biopharmaceuticals by MS-based 'multi-attribute method': advantages and challenges.
    Zhang Y; Guo J
    Bioanalysis; 2017 Mar; 9(6):499-502. PubMed ID: 28207284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.